The U.S. Food and Drug Administration (FDA) has approved Scinopharm Taiwan’s glatiramer acetate injection, a generic of Copaxone, to treat multiple sclerosis (MS). Scinopharm is the first pharmaceutical company in Taiwan to win U.S. approval for glatiramer acetate, marking a significant milestone for the country in the global industry, according to a company press release. […]
The post FDA approves generic injection to help manage MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com